It sees what the calcium score can't. A calcium score is the same machine without contrast, and it only picks up plaque that has already hardened — often decades old. Add contrast and the scan lights up the lumen, the actual channel blood flows through, plus the soft plaque that ruptures first and starts the clot 1.
The payoff is prevention, not surgery. The 41% drop came from doctors starting statins and antiplatelets earlier on the strength of what the scan showed, with no extra stenting 2. The 10-year follow-up held the gain 3. An abnormal scan almost never means a stent; stable disease is treated with medicine first 4.
Any plaque counts. Even non-obstructive plaque, the kind too small to pinch the artery, roughly doubles your 10-year heart-attack risk versus clean arteries 5. It is now the first-line test for stable chest pain in the US, European, and UK guidelines 6 7.
This is a test you ask for, not one you show up and buy. Bring these to your GP or a cardiologist.
The scan itself is a quiet morning; the follow-up is the intervention.
- Same week: nothing changes. You go home and wait a few days for the report.
- Clean scan: obstructive disease is ruled out for years, and the cardiac worry closes.
- Plaque found: a high-intensity statin starts, blood pressure gets a tighter target, and the family conversation gets serious.
- Five years on: the SCOT-HEART trajectory puts your heart-attack odds near half of what they were 2.
Radiation runs about 2.7 millisieverts on modern scanners — roughly nine months of ordinary background exposure, and under 1 on the best machines 8. US cash prices run $500–$2,000; in the UK and much of Europe it is publicly funded under the chest-pain pathway.
The fine print — when to skip it, and what people get wrong
"My calcium score was zero, so I'm fine" is the biggest miss. A zero calcium score can sit on top of soft plaque the contrast scan sees plainly 1. And "no obstructive disease" is not all-clear: any plaque still earns aggressive prevention 5.
Skip or substitute if you have a severe iodine-contrast allergy 9, an eGFR under 30, or a calcium score above ~1,000, where old calcium blurs the picture. Pregnancy usually defers.
- 1Williams MC et al. (2019). Coronary Artery Plaque Characteristics Associated With Adverse Outcomes in the SCOT-HEART Study. Journal of the American College of Cardiology. link
- 2SCOT-HEART Investigators (2018). Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. New England Journal of Medicine. link
- 3Newby DE et al. (2024). 10-year clinical outcomes of a CT angiography-guided diagnostic pathway for stable chest pain in the SCOT-HEART trial. The Lancet. link
- 4Maron DJ et al. (2020). Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine. link
- 5Mortensen MB et al. (2023). Coronary Atherosclerosis Detected by Computed Tomography Angiography to Identify People at Risk of Atherosclerotic Cardiovascular Disease. European Heart Journal. link
- 6Gulati M et al. (2021). 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. link
- 7Knuuti J et al. (2020). 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. link
- 8Stocker TJ et al. (2018). Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI). European Heart Journal. link
- 9American College of Radiology (2023). ACR Manual on Contrast Media (2023 edition). link
Coronary CT Angiography
Single 20-30 minute appointment with brief NPO and caffeine-avoidance prep; oral beta-blocker pre-medication; one IV. No follow-up effort beyond the result conversation.
US cash prices $500-$2,000, insurance-negotiated rates often $250-$700; UK NHS-funded under NICE pathway. Typically a one-time outlay rather than recurring.
Two pivotal RCTs (SCOT-HEART, PROMISE) totalling >14,000 patients; class I indication in AHA/ACC 2021 chest pain guideline, ESC 2019 chronic coronary syndromes guideline, and NICE CG95; 10-year mortality/MI follow-up confirms durability (Newby et al., Lancet 2024). Not 5 because randomised mortality data in asymptomatic-screening populations is absent.
SCOT-HEART (NEJM 2018) reported a 41% reduction in fatal/non-fatal MI at 5 years in the CCTA-guided arm versus standard care, driven by appropriate initiation of preventive therapy; the 10-year extension (Lancet 2024) sustained the benefit. The effect is real but mediated through the downstream prevention, not the scan itself.
The scan itself is diagnostic, not therapeutic — the short-term felt effect is modest: clarity (or the absence of it) and, for many patients, the start of guideline-directed medical therapy (statins, BP control) within weeks. McEvoy et al. (Arch Intern Med 2010) documented behaviour change in low-risk patients after CCTA.
A clean scan resolves cardiac anxiety with near-100% negative predictive value for years (Knuuti et al., Eur Heart J 2020). The flip side: incidental findings (lung nodules, thyroid nodules) occur in 10-30% of scans and can trigger workup-related anxiety. Net effect mild and patient-dependent.